Drug intelligence / Profile preview

VXA-NVV-109

Development stage: Unknown
Lead developer: Vaxart
Modality: Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Adenoviral Vectors → Other Viral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Oral

Overview

VXA-NVV-109 is an oral, bivalent norovirus vaccine candidate developed by Vaxart Inc. It is designed to prevent illness from norovirus, a highly contagious virus that causes vomiting and diarrhea. The vaccine consists of two monovalent components, VXA-G1.1-NN (Norovirus GI.1 Norwalk VP1 Vaccine) and VXA-G2.4-NS (Norovirus GII.4 Sydney VP1 Vaccine). It utilizes an E1-/E3-Deleted Replication-Defective Recombinant Adenovirus 5 vector with a double-stranded ribonucleic acid (dsRNA) adjuvant. The vaccine vector encodes for the full-length VP1 gene from the Norwalk virus (GI.1) and GII.4 Sydney VP1. Formulated as an enteric-coated tablet, VXA-NVV-109 aims to generate both systemic and mucosal immunity. Vaxart's proprietary delivery platform allows for oral administration and stability at room temperature.

Brand names: VXA-G1.1-NN + VXA-GII.4-NS
Other names: Norovirus G1.1 and G2.4 Vaccineoral pill bivalent norovirus vaccine candidate

Targets

GI.1 VP1 (Norovirus GI.1 VP1)GII.17 VP1 (Norovirus GII.17 VP1)TLR3 (Toll-like receptor 3)

Beyond the preview

Go deeper on VXA-NVV-109.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VXA-NVV-109.

Explore the full profile